JPWO2021008501A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021008501A5
JPWO2021008501A5 JP2022502030A JP2022502030A JPWO2021008501A5 JP WO2021008501 A5 JPWO2021008501 A5 JP WO2021008501A5 JP 2022502030 A JP2022502030 A JP 2022502030A JP 2022502030 A JP2022502030 A JP 2022502030A JP WO2021008501 A5 JPWO2021008501 A5 JP WO2021008501A5
Authority
JP
Japan
Prior art keywords
vaccinia virus
gene
cancer
pharmaceutical composition
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022502030A
Other languages
English (en)
Japanese (ja)
Other versions
JP7643739B2 (ja
JP2022540868A5 (https=
JP2022540868A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/101727 external-priority patent/WO2021008501A1/en
Publication of JP2022540868A publication Critical patent/JP2022540868A/ja
Publication of JPWO2021008501A5 publication Critical patent/JPWO2021008501A5/ja
Publication of JP2022540868A5 publication Critical patent/JP2022540868A5/ja
Application granted granted Critical
Publication of JP7643739B2 publication Critical patent/JP7643739B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022502030A 2019-07-12 2020-07-13 遺伝子組換えワクシニアウイルス Active JP7643739B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962873221P 2019-07-12 2019-07-12
US62/873,221 2019-07-12
PCT/CN2020/101727 WO2021008501A1 (en) 2019-07-12 2020-07-13 Engineered vaccinia virus

Publications (4)

Publication Number Publication Date
JP2022540868A JP2022540868A (ja) 2022-09-20
JPWO2021008501A5 true JPWO2021008501A5 (https=) 2024-09-27
JP2022540868A5 JP2022540868A5 (https=) 2024-09-27
JP7643739B2 JP7643739B2 (ja) 2025-03-11

Family

ID=74102574

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502030A Active JP7643739B2 (ja) 2019-07-12 2020-07-13 遺伝子組換えワクシニアウイルス

Country Status (5)

Country Link
US (2) US11739302B2 (https=)
EP (1) EP3996743A4 (https=)
JP (1) JP7643739B2 (https=)
CN (1) CN114144196B (https=)
WO (1) WO2021008501A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117004579B (zh) * 2023-06-29 2024-11-15 苏州恩立维生物科技有限公司 重组溶瘤牛痘病毒及其应用
WO2025157196A1 (zh) * 2024-01-24 2025-07-31 深圳市华药康明生物药业有限责任公司 经修饰的痘苗病毒及其用途
CN120349429B (zh) * 2025-06-25 2025-08-22 武汉大学人民医院（湖北省人民医院） 一种基于hic1功能结构域优化的重组蛋白及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7300774B1 (en) * 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
MXPA04012116A (es) * 2002-06-07 2005-04-19 Zymogenetics Inc Uso del il-21 en cancer y otras aplicaciones terapeuticas.
US20050163805A1 (en) * 2002-10-01 2005-07-28 O'neill Luke A.J. Orthopoxvirus vectors, genes and products thereof
US20060275794A1 (en) * 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
WO2012040266A2 (en) * 2010-09-24 2012-03-29 University Of Miami Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines
GB201405834D0 (en) * 2014-04-01 2014-05-14 Univ London Queen Mary Oncolytic virus
EP3480307B1 (en) * 2016-05-30 2021-06-23 Astellas Pharma Inc. New genetically-modified vaccinia virus
US10888594B2 (en) * 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
BR112021004692A2 (pt) * 2018-09-15 2021-06-08 Memorial Sloan Kettering Cancer Center poxvírus recombinantes para imunoterapia de câncer

Similar Documents

Publication Publication Date Title
AU2018230046B9 (en) Recombinant Herpes simplex virus and use thereof
ES2204922T3 (es) Terapia genica anticancerosa por modulacion de la respuesta inmunitaria y/o inflamatoria.
CN109554353B (zh) 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
US20090053186A1 (en) Therapy for primary and metastatic cancers
JP2019500909A5 (https=)
US20220213161A1 (en) Modified interleukin 12 and use thereof in preparing drugs for treating tumours
US20210138008A1 (en) Recombinant oncolytic virus composition and use thereof
WO2019080537A1 (zh) 包含溶瘤病毒和car-nk细胞的治疗剂及应用、药盒、治疗肿瘤和/或癌症的方法
WO2024113714A9 (zh) 敲低nkg2a基因的car-免疫细胞及其用途
JPWO2019089755A5 (https=)
JP7643739B2 (ja) 遺伝子組換えワクシニアウイルス
JPWO2021008501A5 (https=)
Shakiba et al. Recombinant strains of oncolytic vaccinia virus for cancer immunotherapy
AU2020103637A4 (en) Recombinant oncolytic herpes simplex virus type ii and its pharmaceutical composition
WO2022001080A1 (zh) 一种重组单纯疱疹病毒及其构建方法
Indrová et al. Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and-deficient tumours
KR20220054826A (ko) 항암바이러스, 면역관문억제제 및 히드록시유레아를 유효성분으로 포함하는 암 치료용 약학 조성물
JP2024523314A (ja) Ｔｎｆｓｆ－ｌ融合タンパク質およびその使用
Kesmodel et al. Gene therapy for cancer and metastatic disease
CN115605586B (zh) 工程化溶瘤腺病毒
Du Molecule-Targeted Drugs That Treat Colorectal Cancer
KR20240134204A (ko) 암 치료를 위한 면역자극 단백질을 코딩하는 재조합 오르토폭스 바이러스 벡터
JP2024177358A (ja) 腫瘍溶解性遺伝子改変麻疹ウイルスの新規用途
AU729199B2 (en) Composition for use in the treatment of tumours and the immunization of humans and animals
WO2007068487A2 (en) Tumour treatment with treg down-regulating active agents